(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 September 2021 (30.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/195297 A1

(51) International Patent Classification:
A61K 31/57 (2006.01) *A61K 31/513* (2006.01)
A61K 31/427 (2006.01) *A61K 31/706* (2006.01)
A61K 31/437 (2006.01) *A61K 45/06* (2006.01)
A61K 31/5025 (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:
PCT/US2021/024010

(22) International Filing Date:
24 March 2021 (24.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/994,803	25 March 2020 (25.03.2020)	US
62/994,805	25 March 2020 (25.03.2020)	US
63/000,418	26 March 2020 (26.03.2020)	US
63/000,415	26 March 2020 (26.03.2020)	US
63/006,672	07 April 2020 (07.04.2020)	US
63/006,671	07 April 2020 (07.04.2020)	US
63/063,803	10 August 2020 (10.08.2020)	US
63/063,780	10 August 2020 (10.08.2020)	US

(71) Applicant: **SAGE THERAPEUTICS, INC.** [US/US]; 215 First Street, Cambridge, MA 02142 (US).

(72) Inventor: **KANES, Stephen Jay**; 1122 Brynlawn Road, Brylawn, PA 19085 (US).


(74) Agent: **DOYLE, Kathryn D.**; Honigman LLP, 650 Trade Centre Way, Suite 200, Kalamazoo, MI 49002-0402 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: USE OF AGENTS FOR TREATMENT OF RESPIRATORY CONDITIONS



(1)



(2)

(57) Abstract: Provided herein are methods for treating a symptom of a respiratory condition or a disease associated with a coronavirus, in a subject, comprising administering to the subject an effective amount of an agent selected from the group consisting of Compound (1) and Compound (2), or a pharmaceutically acceptable salt thereof.

WO 2021/195297 A1